Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Regeneron
Regeneron
Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
Clinical Trials Arena
Regeneron
clinical trials
bispecific antibodies
linvoseltamab
Flag link:
FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
Regeneron, J&J Win HHS Funding to Develop Next-Gen COVID Products
Regeneron, J&J Win HHS Funding to Develop Next-Gen COVID Products
BioSpace
HHS
Regeneron
JNJ
COVID-19
funding
Flag link:
Regeneron Expands Eylea’s Label with High-Dose Approval
Regeneron Expands Eylea’s Label with High-Dose Approval
BioSpace
Regeneron
Eylea
FDA
Flag link:
Regeneron’s Antibody Gets FDA Approval for Ultra-Rare Hereditary Disease
Regeneron’s Antibody Gets FDA Approval for Ultra-Rare Hereditary Disease
BioSpace
Regeneron
FDA
CHAPLE disease
Veopoz
Flag link:
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
FDA
Ipsen
Revance Therapeutics
Neurocrine
Regeneron
palovarotene
fibrodysplasia ossificans progressiva
Daxxify
cervical dystonia
Ingrezza
chorea
Huntington's disease
pozelimab
CHAPLE disease
Flag link:
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Fierce Pharma
Regeneron
Eylea
age-related macular degeneration
FDA
Flag link:
Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration
Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration
Fierce Biotech
Regeneron
hearing loss
Decibel Therapeutics
gene therapy
M&A
Flag link:
Regeneron expects FDA decision on higher-dose Eylea this year
Regeneron expects FDA decision on higher-dose Eylea this year
Reuters
Regeneron
Eylea
FDA
Flag link:
Moderna, Regeneron post solid earnings, eye a strong finish to 2023
Moderna, Regeneron post solid earnings, eye a strong finish to 2023
Medical Marketing and Media
earnings
Moderna Therapeutics
Regeneron
Flag link:
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Fierce Biotech
Regeneron
prostate cancer
clinical trials
patient deaths
REGN5678
bispecific antibodies
Flag link:
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Ipsen
palovarotene
fibrodysplasia ossificans progressiva
Regeneron
CHAPLE disease
pozelimab
Biomarin
Voxzogo
achondroplasia
Santhera Pharmaceuticals
vamorolone
DMD
Springworks
nirogacestat
desmoid tumors
Flag link:
Scratching the surface of the urticaria pipeline
Scratching the surface of the urticaria pipeline
EP Vantage
chronic urticaria
Sanofi
Dupixent
Regeneron
Novartis
Roche
Xolair
Allakos
AstraZeneca
Celldex Therapeutics
Flag link:
Dupixent goes back-to-back as top Rx, OTC pharma brand in June
Dupixent goes back-to-back as top Rx, OTC pharma brand in June
Medical Marketing and Media
Dupixent
Sanofi
Regeneron
Flag link:
Is Regeneron's Stock in Trouble After This FDA Rejection?
Is Regeneron's Stock in Trouble After This FDA Rejection?
Motley Fool
Regeneron
Eylea
FDA
Flag link:
Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups
Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups
Fierce Pharma
Regeneron
Eylea
FDA
Flag link:
Aslan sells Japanese rights to would-be Dupixent rival for $12M
Aslan sells Japanese rights to would-be Dupixent rival for $12M
Fierce Biotech
Aslan
Dupixent
Japan
eczema
Sanofi
Regeneron
eblasakimab
Flag link:
Dupixent reclaims throne as top Rx, OTC pharma brand in May
Dupixent reclaims throne as top Rx, OTC pharma brand in May
Medical Marketing and Media
Dupixent
Sanofi
Regeneron
DTC advertising
Flag link:
Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma
ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma
Fierce Biotech
ASCO 2023
Regeneron
advanced melanoma
fianlimab
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »